Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:60901
Name lymphoplasmacytic lymphoma
Definition A B-cell lymphoma characterized by the accumulation of monoclonal cells in the bone marrow and peripheral lymphoid tissues, and associated with the production of serum immunoglobulin M (IgM) monoclonal protein.
Source DiseaseOntology.org
Alt Ids DOID:0050747
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma lymphoplasmacytic lymphoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00577278 Phase II Ibritumomab tiuxetan Methotrexate + Sirolimus + Tacrolimus Rituximab Fludarabine + Melphalan A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan Completed USA 0
NCT00602693 Phase I Sirolimus Allopurinol + Cyclophosphamide + Fludarabine T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Completed USA 0
NCT00671112 Phase I Bortezomib + Everolimus Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated USA 0
NCT01732913 Phase III Idelalisib Rituximab Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated USA | ITA | GBR | FRA | ESP | DEU | AUS 12
NCT01732926 Phase III Idelalisib Bendamustine + Rituximab Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 7
NCT01796171 Phase Ib/II Lilotomab Betalutin Rituximab A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01) Completed USA | NLD | ITA | GBR | FRA | ESP | CAN | BEL | AUT | AUS 14
NCT01955499 Phase I Ibrutinib + Lenalidomide Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Active, not recruiting USA | CAN 0
NCT01994382 Phase I Cerdulatinib Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma Completed USA 0
NCT02000934 Phase I Mivavotinib A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies Completed USA | ITA | GBR | ESP 0
NCT02049541 Phase I Buparlisib + Rituximab Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma Completed USA 0
NCT02092909 Phase Ib/II Bazlitoran Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (8400-401) Terminated USA 0
NCT02106091 Phase I AFM11 Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL Terminated USA | DEU 2
NCT02180724 Phase I Acalabrutinib An Open-label, Phase 1b Study of ACP 196 in Subjects With Waldenström Macroglobulinemia Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP 1
NCT02339922 Phase II Ixazomib + Rituximab Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT02367040 Phase III Rituximab Copanlisib Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) Active, not recruiting USA | NZL | ITA | FRA | ESP | DEU | BEL | AUT | AUS 28
NCT02369016 Phase III Copanlisib Phase III Copanlisib in Rituximab-refractory iNHL Completed ITA 9
NCT02384954 Phase Ib/II Nogapendekin alfa inbakicept + Rituximab ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab Terminated USA 0
NCT02457598 Phase I Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies Active, not recruiting USA | GBR | FRA 0
NCT02576496 Phase I Tinostamustine Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Active, not recruiting USA | NLD | ITA | FRA | ESP | DEU 1
NCT02604511 Phase II Ibrutinib Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing Completed USA 0
NCT02626455 Phase III Vincristine Sulfate Prednisone Aldoxorubicin + Cyclophosphamide + Prednisone + Rituximab + Vincristine Sulfate Copanlisib Bendamustine + Rituximab Rituximab Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-4) Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 26
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Active, not recruiting USA 0
NCT02950220 Phase I Ibrutinib + Pembrolizumab Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed USA 0
NCT03010358 Phase Ib/II Entospletinib + Obinutuzumab Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Completed USA 0
NCT03015896 Phase Ib/II Lenalidomide + Nivolumab Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Active, not recruiting USA 0
NCT03037645 Phase Ib/II Vecabrutinib Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers Terminated USA 0
NCT03053440 Phase III Ibrutinib Zanubrutinib A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS 4
NCT03085173 Phase I EGFRt/19-28z/4-1BBL CAR T cells A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies Active, not recruiting USA 0
NCT03133221 Phase II Idelalisib 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Active, not recruiting USA 0
NCT03147885 Phase Ib/II Selinexor Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT03162536 Phase I ARQ 531 Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies Active, not recruiting USA 0
NCT03225716 Phase Ib/II Ibrutinib + Ulocuplumab A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia Active, not recruiting USA 0
NCT03277729 Phase Ib/II CD20 CAR T-cells + Cyclophosphamide + Fludarabine A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Recruiting USA 0
NCT03364231 Phase II Umbralisib Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma Completed USA 0
NCT03479268 Phase I Ibrutinib + MLN4924 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma Active, not recruiting USA 0
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Active, not recruiting USA 0
NCT03498612 Phase II Pembrolizumab Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases Active, not recruiting USA 0
NCT03506373 Phase II Ibrutinib + Ixazomib Ibrutinib and Ixazomib Citrate in Treating Participants With Relapsed or Refractory Waldenstrom Macroglobulinemia Active, not recruiting USA 0
NCT03537482 Phase I APG-2575 APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies Recruiting USA | AUS 0
NCT03557619 Phase I Ethinylestradiol + Levonorgestrel + Venetoclax A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Subjects With Different Hematological Malignancies Recruiting USA | AUS 0
NCT03571828 Phase I AMG562 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma Terminated USA | DEU | CAN | BEL 0
NCT03601819 Phase I Pacritinib Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders Terminated USA 0
NCT03620903 Phase II Rituximab Bortezomib Ibrutinib Efficacy of First Line B-RI for Treatment Naive Waldenstrom's Macroglobulinemia Active, not recruiting DEU 1
NCT03630042 Phase II Pembrolizumab + Rituximab Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia (PembroWM) Completed GBR 0
NCT03679624 Phase II Daratumumab + Ibrutinib Daratumumab Plus Ibrutinib in Patients With Waldenstrom's Macroglobulinemia Terminated USA 0
NCT03711578 Phase II Tenalisib Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) Completed USA | AUS 0
NCT03740529 Phase Ib/II Cyclophosphamide + Doxorubicin + Pirtobrutinib + Prednisone + Rituximab + Vincristine Sulfate Pirtobrutinib + Rituximab + Venetoclax Pirtobrutinib + Venetoclax Pirtobrutinib A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Active, not recruiting USA | ITA | GBR | FRA | AUS 5
NCT03779113 Phase Ib/II HMPL-523 An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma Active, not recruiting USA | ITA | FRA | ESP 3
NCT03786926 Phase Ib/II HMPL-689 Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas Active, not recruiting USA | ITA | FRA | ESP 2
NCT03833180 Phase I VLS-101 A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies Completed USA 0
NCT03884998 Phase I Copanlisib + Nivolumab Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma Active, not recruiting USA 0
NCT03920631 Phase I Nivolumab Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) Withdrawn USA 0
NCT04043845 Phase I Ibrutinib + LY3214996 ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies Withdrawn 0
NCT04052854 Expanded access Zanubrutinib A Single-Arm, Expanded Access Study of Zanubrutinib (BGB3111) in Patients With B-cell Malignancies No longer available USA 0
NCT04061512 Phase II Cyclophosphamide + Dexamethasone + Rituximab Ibrutinib + Rituximab Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia (RAINBOW) Recruiting GBR 0
NCT04072458 Phase I BP1002 A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies Recruiting USA 0
NCT04115059 Phase I Dasatinib Dasatinib In Waldenstrom Macroglobulinemia Terminated USA 0
NCT04260217 Phase I APG-2575 APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenstrom Macroglobulinemia (MAPLE-1) Recruiting USA | AUS 1
NCT04263480 Phase III Carfilzomib + Ibrutinib Ibrutinib Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1) Recruiting DEU | AUT 1
NCT04273139 Phase II Ibrutinib + Venetoclax Ibrutinib + Venetoclax in Untreated WM Active, not recruiting USA 0
NCT04274738 Phase I Ibrutinib + X4P-001 A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 Completed USA 1
NCT04277637 Phase I BGB-11417 + Zanubrutinib BGB-11417 Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies Recruiting USA | NZL | ITA | GBR | ESP | DEU | AUS 0
NCT04401020 Phase I SAR442257 First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL Active, not recruiting USA | ESP 3
NCT04540796 Phase I JNJ-75348780 A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Active, not recruiting USA | GBR | FRA | ESP | AUS 3
NCT04545762 Phase I Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Recruiting USA 0
NCT04578600 Phase I Azacitidine + Lenalidomide + Obinutuzumab CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Active, not recruiting USA 0
NCT04624906 Phase II Acalabrutinib + Bendamustine + Rituximab Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia (BRAWM) Recruiting CAN 0
NCT04635683 Phase I Lenalidomide + Ublituximab + Umbralisib Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Withdrawn 0
NCT04665115 Phase II Ibrutinib Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) Withdrawn USA 0
NCT04728893 Phase II ARQ 531 Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 14
NCT04771572 Phase I LP-118 Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. Recruiting USA 0
NCT04775745 Phase I LP-168 Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. Recruiting USA 0
NCT04799275 Phase II Azacitidine + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Recruiting USA 0
NCT04830137 Phase I NX-2127 A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Active, not recruiting USA 0
NCT04840602 Phase II Ibrutinib + Rituximab + Venetoclax Ibrutinib + Rituximab Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma Recruiting USA 0
NCT04842877 Phase II DS-3201b Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma Active, not recruiting FRA | BEL 0
NCT04861779 Phase I HSK29116 A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting AUS 1
NCT04883437 Phase II Acalabrutinib + Obinutuzumab Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Recruiting USA 0
NCT05003141 Phase I PSB202 PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies Unknown status USA | AUS 1
NCT05006716 Phase I BGB-16673 A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies Recruiting USA | ITA | FRA | ESP | DEU | CAN | AUS 4
NCT05020678 Phase I Cyclophosphamide + Fludarabine NKX019 NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers Recruiting USA | AUS 0
NCT05065554 Phase II Acalabrutinib + Rituximab ACALA-R In Anti-MAG Neuropathy Mediated Neuropathy Recruiting USA 0
NCT05131022 Phase I NX-5948 Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies Recruiting USA | NLD | GBR 0
NCT05172700 Expanded access Pirtobrutinib Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer Available 0
NCT05256641 Phase Ib/II Acalabrutinib Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma Recruiting USA 0
NCT05275504 Phase I TT-01488 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies Recruiting USA 0
NCT05293912 Phase I SG2501 SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma. Recruiting USA 0
NCT05424822 Phase I JNJ-80948543 A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Recruiting USA | FRA | AUS 4
NCT05537766 Phase II Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25) Recruiting USA | NLD | ITA | FRA | ESP | DEU | AUT 1
NCT05602363 Phase I AS-1763 AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma Recruiting USA 0
NCT05702853 Phase Ib/II CD19-CD34 CAR transduced T cells Cyclophosphamide + Fludarabine Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL Recruiting USA 0
NCT05734495 Phase II Pirtobrutinib + Venetoclax Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia Recruiting USA 0
NCT05753501 Phase I ABBV-101 Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies Recruiting USA 2
NCT05780034 Phase I AC0676 A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies Recruiting USA 0
NCT05797233 Phase I Cyclophosphamide + Fludarabine Anti-CD19-CD20 CAR T cells Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies Recruiting USA 0
NCT05952037 Phase II BGB-11417 Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenstrom's Macroglobulinemia Recruiting USA | GBR | FRA | ESP | AUS 1
NCT06340737 Phase I Anti-CD22 CAR T cells AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas Recruiting USA 0